Product Description
Arformoterol inhalation is used to control wheezing, shortness of breath, coughing, and chest tightness caused by chronic obstructive pulmonary disease (COPD; a group of lung diseases, which includes chronic bronchitis and emphysema). Arformoterol is in a class of medications called long-acting beta agonists (LABAs). It works by relaxing and opening air passages in the lungs, making it easier to breathe. (Sourced from: https://medlineplus.gov/druginfo/meds/a607061.html)
Mechanisms of Action: ADRB2 Agonist, LAB Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Inhalant
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Bangladesh | India | Turkey | United States
Approved Indications: None
Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/21/2023 |
News Article |
Bronchial Spasms Treatment Market Size, Growth 2023-2031 |
|
09/02/2023 |
News Article |
Despite the challenges posed by Covid-19, the global Anti Asthma Drugs market Size is projected to grow at a CAGR of 5.6% during the 2023 to 2030 period |
|
08/24/2022 |
News Article |
Calyptus Pharmaceuticals Announces Approval of Arformoterol Tartrate Inhalation Solution, EQ 0.015 mg Base/2 ml |
|
08/24/2021 |
News Article |
Chronic Obstructive Pulmonary Disease (COPD) - Market Insight, Epidemiology and Market Forecast - 2030 |